Pfizer Venture Investments
Venture capital · New York, New York, United States
Portfolio collected from the firm’s website, last checked Jun 28, 2026.Raises and exits come from each company’s own SEC and company records.
16Deep-tech portfolio13 active
3Portfolio exitsAcquired or listed
1Raises, 12 monthsLatest: TRIANA Biomedicines
21Co-investorsShare a portfolio company
Portfolio · 16 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| TRIANA Biomedicines | Biotech | Active | Dec 4, 2025 | $170.9M |
| ReCode Therapeutics | Biotech | Active | Oct 23, 2025 | $97.4M |
| Enlaza Therapeutics | Biotech | Active | Sep 11, 2025 | $103.0M |
| Autobahn Therapeutics | Biotech | Active | Aug 1, 2024 | $100.8M |
| Beam Therapeutics | Biotech | Active | Mar 26, 2019 | $180.0M |
| Anaveon | Biotech | Active | — | — |
| Cartography Biosciences | Biotech | Active | — | — |
| Curve Therapeutics | Biotech | Active | — | — |
| Enara Bio | Biotech | Active | — | — |
| HotSpot Therapeutics | Biotech | Active | — | — |
| Mission Therapeutics | Biotech | Active | — | — |
| Mozart Therapeutics | Biotech | Active | — | — |
| Oblenio Bio | Biotech | Active | — | — |
| Interius BioTherapeutics | Biotech | Acquired | Jun 3, 2024 | $118.1M |
| Jnana Therapeutics | Biotech | Acquired | Jan 26, 2024 | $110.0M |
| Morphic Therapeutic | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#24
Portfolio exits#69
Raises, 12 months#22
Co-investors#101
Co-investors
- Atlas VentureVenture capital3 shared
- Avalon VenturesVenture capital3 shared
- RA CapitalVenture capital3 shared
- Amgen VenturesVenture capital2 shared
- Bain Capital Life SciencesVenture capital2 shared
- AbingworthVenture capital1 shared
- Alexandria Venture InvestmentsVenture capital1 shared
- Andreessen HorowitzVenture capital1 shared
- ARCH VentureVenture capital1 shared
- Cormorant Asset ManagementVenture capital1 shared
Sectors
- Biotech16
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.